Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD Claudia Costa1

European Respiratory Journal

Volumn 47, Issue 4, 2016, Pages 1093-1102

  Traves, Suzanne L ^a   Tudhope, Susan J ^a   Fenwick, Peter S ^a   Belchamber, Kylie B R ^a   Russell, Richard E K ^b   Barnes, Peter J ^a   Donnelly, Louise E ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b King Edward King VII Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; LIGAND; CCR5 PROTEIN, HUMAN; CHEMOKINE; CXCR3 PROTEIN, HUMAN;

ADULT; ARTICLE; CELL ASSAY; CELL ISOLATION; CHEMOTAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; MACROPHAGE; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; SMOKING; T LYMPHOCYTE; AGED; CD8+ T LYMPHOCYTE; CELL MOTION; CYTOLOGY; FLOW CYTOMETRY; INFLAMMATION; LUNG; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL;

ADULT; AGED; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CHEMOKINES; CHEMOTAXIS; FEMALE; FLOW CYTOMETRY; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; LIGANDS; LUNG; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, CCR5; RECEPTORS, CXCR3;

EID: 84963995279     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01642-2015     Document Type: Article

References (35)

1. Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 26-33.
2. Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med 2014; 35: 71-86.
3. Lams BE, Sousa AR, Rees PJ, et al. Immunopathology of the small-airway submucosa in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1518-1523.
4. O'Shaughnessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155: 852-857.
5. Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest 2000; 117: Suppl. 1, 251S-260S.
6. Saetta M, Baraldo S, Corbino L, et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 711-717.
7. Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998; 158: 1277-1285.
8. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-280.
9. Barnes PJ. Alveolar macrophages as orchestrators of COPD. COPD 2004; 1: 50-70.
10. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997; 155: 449-453.
11. Traves SL, Smith SJ, Barnes PJ, et al. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: A role for CXCR2. J Leukoc Biol 2004; 76: 441-450.
12. Tomita K, Caramori G, Lim S, et al. Increased p21(CIP1/WAF1) and B cell lymphoma leukemia-x(L) expression and reduced apoptosis in alveolar macrophages from smokers. Am J Respir Crit Care Med 2002; 166: 724-731.
13. Panina-Bordignon P, D'Ambrosio D. Chemokines and their receptors in asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2003; 9: 104-110.
14. Tzanakis N, Chrysofakis G, Tsoumakidou M, et al. Induced sputum CD8+ T-lymphocyte subpopulations in chronic obstructive pulmonary disease. Respir Med 2004; 98: 57-65.
15. Campbell DJ, Debes GF, Johnston B, et al. Targeting T cell responses by selective chemokine receptor expression. Semin Immunol 2003; 15: 277-286.
16. Sallusto F, Kremmer E, Palermo B, et al. Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur J Immunol 1999; 29: 2037-2045.
17. Annunziato F, Cosmi L, Galli G, et al. Assessment of chemokine receptor expression by human Th1 and Th2 cells in vitro and in vivo. J Leukoc Biol 1999; 65: 691-699.
18. Freeman CM, Curtis JL, Chensue SW. CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8+ cells correlates with chronic obstructive pulmonary disease severity. Am J Pathol 2007; 171: 767-776.
19. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52: 145-176.
20. Kelsen SG, Mardini IA, Zhou S, et al. A technique to harvest viable tracheobronchial epithelial cells from living human donors. Am J Respir Cell Mol Biol 1992; 7: 66-72.
21. Petkovic V, Moghini C, Paoletti S, et al. I-TAC/CXCL11 is a natural antagonist for CCR5. J Leukoc Biol 2004; 76: 701-708.
22. Grumelli S, Corry DB, Song LZ, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 2004; 1: e8.
23. Kelsen SG, Aksoy MO, Georgy M, et al. Lymphoid follicle cells in chronic obstructive pulmonary disease overexpress the chemokine receptor CXCR3. Am J Respir Crit Care Med 2009; 179: 799-805.
24. Curtis JL, Freeman CM, Hogg JC. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research. Proc Am Thorac Soc 2007; 4: 512-521.
25. Costa C, Rufino R, Traves SL, et al. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 2008; 133: 26-33.
26. Global Initative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html Date last accessed: August 10, 2015. Last updated 2014.
27. Wilkinson PC. Micropore filter methods for leukocyte chemotaxis. Methods Enzymol 1988; 162: 38-50.
28. Matsushima K, Larsen CG, DuBois GC, et al. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989; 169: 1485-1490.
29. Medina JC, Tularik Inc., assignee. CXCR3 Antagonists. Patent WO/2002/083143. 2002.
30. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002; 2: 106-115.
31. Koch A, Gaczkowski M, Sturton G, et al. Modification of surface antigens in blood CD8+ T-lymphocytes in COPD: effects of smoking. Eur Respir J 2007; 29: 42-50.
32. Brozyna S, Ahern J, Hodge G, et al. Chemotactic mediators of Th1 T-cell trafficking in smokers and COPD patients. COPD 2009; 6: 4-16.
33. Morissette MC, Parent J, Milot J. Perforin, granzyme B, and FasL expression by peripheral blood T lymphocytes in emphysema. Respir Res 2007; 8: 62.
34. Cole KE, Strick CA, Paradis TJ, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): A novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187: 2009-2021.
35. Fadel H, Temesgen Z. Maraviroc. Drugs Today 2007; 43: 749-758.